| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.0012 | 1 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.0013 | 1 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.0021 | 1 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.0041 | 1 |
| mRNA | JQ-1 | GDSC1000 | pan-cancer | AAC | 0.001 | 1 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | -0.001 | 1 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.00071 | 1 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | -0.001 | 1 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.00053 | 1 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.00054 | 1 |